Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman, M S

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Sep 2012 - 2356-2362 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdr620 doi


Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Disease-Free Survival
Female
Humans
Immunization, Passive
Induction Chemotherapy
Kaplan-Meier Estimate
Lymphoma, Follicular--drug therapy
Male
Middle Aged
Rituximab
Severity of Illness Index
Treatment Outcome
Young Adult